Abbvie Inc.
A global biopharmaceutical company, AbbVie develops and sells medicines for immune, nerve, and cancer conditions — brands include Skyrizi, Rinvoq, Humira, Botox, and Imbruvica — as well as cosmetic treatments like Botox Cosmetic and the Juvederm line. It was born in 2013 when Abbott Laboratories split, spinning off its drug business into a fresh company. Fun fact: the name blends "Abb" (from Abbott) with "Vie," echoing the Latin word for "life," and insiders noted it conveniently rhymes with "R&D."
Granted 703.5K · Sold 586.6K
Granted 224.6K · Sold 95.2K
Granted 250.3K · Sold 68.9K
Granted 3.6K
Granted 46.6K
Granted 210.2K · Sold 117.8K
Granted 92.3K · Sold 37.3K
Granted 3.6K
Granted 39.8K
Granted 2.5K
Granted 3.6K
Granted 114.0K · Sold 31.8K
Granted 2.5K
Granted 3.6K
Granted 3.6K
Granted 3.6K
Granted 3.6K
Granted 126.1K · Sold 98.4K
Granted 3.6K
Granted 2.5K
Granted 38.5K · Sold 25.9K
Granted 159.9K · Sold 126.8K
Granted 2.3K
Granted 3.6K
Granted 3.6K
Granted 6.1K · Sold 5.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Gonzalez Richard ADirector · 26 transactions | -31.6% | 386.5Kas of Mar 2025 | 703.5K | — | 586.6K |
| Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER · 20 transactions | -12.3% | 204.4K | 224.6K | — | 95.2K |
| Michael Robert A.CHAIRMAN OF THE BOARD AND CEO, Director · 19 transactions | +81.2% | 178.7K | 250.3K | — | 68.9K |
| Freyman Thomas CDirector · 3 transactions | — | 133.8K | 3.6K | — | — |
| Hudson Thomas JSVP, CSO, GLOBAL RESEARCH · 5 transactions | +31.9% | 107.3Kas of Feb 2024 | 46.6K | — | — |
| Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER · 22 transactions | +35.7% | 84.5K | 210.2K | — | 117.8K |
| Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER · 19 transactions | +26.5% | 74.4K | 92.3K | — | 37.3K |
| Rapp Edward JDirector · 3 transactions | +39.4% | 56.4K | 3.6K | — | — |
| Thakkar RoopalEVP, R&D and CSO · 15 transactions | — | 55.4K | 39.8K | — | — |
| Tilton Glenn FDirector · 2 transactions | +5.1% | 51.9Kas of May 2025 | 2.5K | — | — |
| Austin Roxanne SDirector · 3 transactions | +10.1% | 39.6K | 3.6K | — | — |
| Reents Scott TEVP, CHIEF FINANCIAL OFFICER · 18 transactions | +2237.4% | 38.8K | 114.0K | — | 31.8K |
| Alpern Robert JDirector · 3 transactions | +8% | 35.6Kas of May 2025 | 2.5K | — | — |
| Waddell Frederick HDirector · 3 transactions | +13.8% | 30.1K | 3.6K | — | — |
| Burnside William H.L.Director · 3 transactions | +14.9% | 28.1K | 3.6K | — | — |
| Hart Brett JDirector · 3 transactions | +21.5% | 20.6K | 3.6K | — | — |
| Meyer Melody BDirector · 3 transactions | +26.1% | 17.6K | 3.6K | — | — |
| Siatis Perry CEVP, GC AND SECRETARY · 39 transactions | +26% | 17.5K | 126.1K | — | 98.4K |
| Roberts Rebecca BDirector · 3 transactions | +32.5% | 14.8K | 3.6K | — | — |
| Crum Demetris DEVP, CHIEF HR OFFICER · 3 transactions | — | 7.9K | 2.5K | — | — |
| Buckbee Kevin KSVP, CONTROLLER · 17 transactions | +8.9% | 7.8Kas of Feb 2025 | 38.5K | — | 25.9K |
| Richmond Timothy J.EVP, CHIEF HR OFFICER · 25 transactions | -80% | 6.1Kas of Mar 2025 | 159.9K | — | 126.8K |
| Falk Thomas JDirector · 2 transactions | — | 5.3K | 2.3K | — | — |
| Davis Jennifer L.Director · 3 transactions | — | 3.6K | 3.6K | — | — |
| Quaggin Susan EDirector · 3 transactions | — | 3.6K | 3.6K | — | — |
| Purdue David RyanSVP, Controller · 6 transactions | — | 1.1K | 6.1K | — | 5.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.19M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.